VCM
IRD

Vigilant Capital Management’s Opus Genetics IRD Stock Holding History

Vigilant Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-17
Closed -$1K – 490
2018
Q4 		$1K Hold
17
– – ﹤0.01% 427
2018
Q3 		$1K Hold
17
– – ﹤0.01% 452
2018
Q2 		$1K Hold
17
– – ﹤0.01% 457
2018
Q1 		$1K Hold
17
– – ﹤0.01% 415
2017
Q4 		$2K Hold
17
– – ﹤0.01% 394
2017
Q3 		$2K Hold
17
– – ﹤0.01% 291
2017
Q2 		$2K Hold
17
– – ﹤0.01% 271
2017
Q1 		$4K Buy
+17
New +$2.2K ﹤0.01% 259

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
FIM
Frontier Investment Management Dallas, Texas $1.62B AUM 1.86% 1-Year Est. Return

Vigilant Capital Management's IRD Position: Q1 2019 in Review

Vigilant Capital Management sold out of Opus Genetics (IRD) in Q1 2019, closing a stake of 17 shares — an estimated $1K sold.

Vigilant Capital Management first reported a position in IRD in Q1 2017 and held it in 8 quarters. The position peaked at $4K in Q1 2017. 28 funds tracked by Wall St. Rank hold IRD as of Q1 2019.

  • Vigilant Capital Management reported no remaining Opus Genetics position as of Q1 2019 after selling out during the quarter.
  • Vigilant Capital Management sold 17 Opus Genetics shares in Q1 2019, an estimated $1K.
  • Vigilant Capital Management first reported a position in Opus Genetics in Q1 2017 and held it in 8 quarters.
  • Vigilant Capital Management's Opus Genetics position peaked at $4K in Q1 2017.
  • 28 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2019.

Based on Vigilant Capital Management's 13F filing for Q1 2019, filed 9 Apr 2019.